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Background: Serum CYFRA 21–1 is one of the most important serum markers in the diagnosis of non-small cell
lung cancer (NSCLC), especially squamous-cell carcinoma. However, it remains unknown whether pretreatment
serum CYFRA 21–1 values (PCV) may also have prognostic implications in patients with advanced lung
adenocarcinoma.
Methods: We retrospectively reviewed the data of 284 patients (pts) who were diagnosed as having advanced
lung adenocarcinoma and had received initial therapy.
Results: Of the study subjects, 121 pts (43%) had activating epidermal growth factor receptor (EGFR) mutations (Mt+),
while the remaining 163 pts (57%) had wild-type EGFR (Mt-). Univariate analysis identified gender (male/ female), ECOG
performance status (PS) (0-1/ ≥2), PCV (<2.2 ng/ml/ ≥2.2 ng/ml), EGFR mutation status (Mt+/ Mt-), pretreatment serum
CEA values (<5.0 ng/ml/ ≥5.0 ng/ml), smoking history (yes/ no) and EGFR-TKI treatment (yes/ no) as prognostic factors
(p = .008, p < .0001, p < .0001, p < .0001, p = .036, p = .0012, p < .0001 respectively). Cox's multivariate regression
analysis identified PCV < 2.2ng/ml as the only factor significantly associated with prolonged survival (p < .0001, hazard
ratio: 0.43, 95% CI 0.31-0.59), after adjustments for PS (p < .0001), EGFR mutation status (p = .0069), date of start of initial
therapy (p = .07), gender (p = .75), serum CEA level (p = .63), smoking history (p = .39) and EGFR-TKI treatment
(p = .20). Furthermore, pts with Mt+ and PCV of <2.2 ng/ml had a more favorable prognosis than those with Mt+ and
PCV of ≥2.2 ng/ml (MST: 67.0 vs. 21.0 months, p < .0001), and patients with Mt- and PCV of <2.2 ng/ml had a more
favorable prognosis than those with Mt- and PCV of ≥2.2 ng/ml (MST: 24.1 vs. 10.2 months, p < .0001).
Conclusion: PCV may be a potential independent prognostic factor in both Mt+ and Mt- patients with advanced lung
adenocarcinoma.
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Lung cancer is the leading cause of cancer death, and at
present, there exists no cure of stage IV non-small cell
lung cancer (NSCLC) [1]. Adenocarcinoma and squa-
mous cell carcinoma are the most common histological
subtypes of lung cancer and account for about 70% of all
lung cancers [2]. The folate antagonist pemetrexed has
been shown to exhibit efficacy against non-squamous
cell lung cancers [3], and is currently used in combination
with cisplatin as a standard treatment regimen for patients
with non-squamous cell lung carcinoma. Chemotherapy
with the angiogenesis inhibitor bevacizumab administered
in combination with platinum agents has also been shown
to exhibit favorable efficacy against non-squamous cell
lung carcinoma [4,5]. Somatic gain-of-function mutations
in exons encoding the EGFR tyrosine kinase domain have
been identified in NSCLC [6,7]. Several previous studies
have reported prolongation of the survival time in patients
with EGFR-mutation-positive lung carcinomas treated
with EGFR-tyrosine kinase inhibitors (TKIs) [8-11], there-
fore, EGFR-TKIs are widely used in medical practice.
EGFR mutations occur more frequently in lung cancer pa-
tients who are Asians, females and non-smokers with the
histological subtype of adenocarcinoma [12-14]. On the
other hand, while there have also been scattered reports of
EGFR mutations among cases of lung squamous-cell car-
cinoma [15-17], a recent report showed that there were
no EGFR mutation-positive cases among lung cancer pa-
tients with pure squamous cell carcinoma [18,19].
CYFRA 21–1 is a fragment of cytokeratin (CK) 19.
CKs, which are now called keratins, are the principal
structural elements of the cytoskeleton (keratin fila-
ments) of epithelial cells, including bronchial epithelial
cells, and have been classified into 20 subtypes based on
differences in the molecular mass and isoelectric point
as determined by 2-dimensional electrophoresis [20,21].
CK types 1–8 are categorized as type I CKs, and CKs
9–20 as type II CKs. Microfilaments are heteropolymers
formed from type I and type II keratins, and constitute the
cytoskeleton [22]. CK19 is a soluble type I CK (acidic
type), and has the lowest molecular mass (40 kDa)
among the CKs. It is expressed in the unstratified or
pseudostratified epithelium lining the bronchial tree
[23], and been reported to be overexpressed in many
lung cancer tissue specimens [24]. The CK expression
patterns in tissues are well-maintained even during the
process of transformation of the tissue from normal to
tumor tissue [25]. Accelerated CK19 degradation occurs
in neoplastically transformed epithelial cells as a result of
increased protease activity of caspase 3, a regulator of the
apoptosis cascade, and fragments are released into the
blood. This results in an increase of the blood CYFRA
21–1 values, because CK19 fragments are recognized by
two monoclonal antibodies [26].Measurement of serum CYFRA 21–1 level is a useful
auxiliary test in the diagnosis of NSCLC, and particularly
high specificity of this test has been reported for the
diagnosis of squamous cell carcinoma of the lung
[27,28]. On the other hand, a meta-analysis also revealed
that serum CYFRA 21–1 may be a useful prognostic fac-
tor in NSCLC patients [29]; analysis of the histological
background in the aforementioned meta-analysis showed
that non-adenocarcinoma accounted for the majority of
cases of NSCLC (65%). There has also been a report
suggesting that serum CYFRA 21–1 levels might serve
as a prognostic factor in patients with recurrent NSCLC
receiving 3rd-line or later gefitinib therapy [30]. Some
studies have suggested the possible prognostic value of
pretreatment serum CYFRA 21–1 values (PCV) in pa-
tients with surgically treated lung adenocarcinoma [31]
and advanced NSCLC [32-34]. However, none of the
studies suggesting serum CYFRA 21–1 as a prognostic
factor in patients with untreated advanced lung adeno-
carcinoma has included the EGFR mutation status as a
variable. Therefore, in the present study, we investigated
the impact of serum CYFRA 21–1 on the prognosis of
untreated advanced lung adenocarcinoma patients.
Methods
Patients
Of patients diagnosed as having primary lung carcinoma
between January 2003 and June 2010 at the Shizuoka
Cancer Center, EGFR mutation analysis was performed
on 424 patients from April 2008 to June 2010. Of these,
284 lung adenocarcinoma patients had received initial
therapy, and we retrospectively reviewed the data of the
163 patients who were found to harbor wild-type EGFR
and 121 patients who were found to harbor activating
EGFR mutations (Figure 1). The following inclusion cri-
teria were set for this study; patients with pathologically
proven adenocarcinoma who had received initial therapy
(including chemotherapy or chemoradiotherapy) and
survived for more than one month; Eastern Cooperative
Oncology Group performance status (ECOG PS) of 3 or
less. The histological and cytological diagnoses were
performed according to the WHO classification criteria
[35]. The study was conducted with the approval of the
Shizuoka cancer center Institutional Review Board #1
(HHS IRB registration number; IRB00006744).
We outsourced some of the clinical laboratory tests,
such as measurement of the tumor markers and EGFR
mutation analysis. Serum CYFRA 21–1 and serum CEA
concentrations were measured at the baseline, before the
initial therapy. The serum CYFRA 21–1 concentration
was measured using a Lumipulse Presto® kit (FUJIREBIO
Inc, Tokyo, Japan), based on a CLEIA (chemiluminescent
enzyme immunoassay) method, while the serum CEA
concentrations were measured using an ARCHITECT® kit
Figure 1 A flow-diagram of the patients included in the analysis.
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performed by fragment analysis using polymerase chain
reaction (PCR) and the cycleave real-time quantitative
PCR technique (SRL Inc, Tokyo, Japan).
The reported upper limit of normal for the diagnosis
of NSCLC and upper limit of the percentiles for healthy
individuals of serum CYFRA 21–1 as measured by EIA
are 3.5 ng/ml and 2.8 ng/ml, respectively [36]. In con-
trast, the reported upper limit of the percentiles for
healthy individuals of serum CYFRA 21–1 measured by
the CLEIA method is 1.6 ng/ml [37], a lower value as
compared to that set for measurement by the EIA
method. Therefore, for our study, we set the cutoff value
for CYFRA 21–1 at 2.2 ng/ml, based on the mean value
for healthy subjects + 3SD [37], a lower value as com-
pared to that set for measurement by the EIA method.
The cutoff value for serum CEA was set at 5.0 ng/ml,
which is the upper limit of normal.
A standard evaluation of the patients, including assess-
ment of the medical history, physical examination and
routine laboratory tests, was performed before each treat-
ment. All patients were staged based on the International
Association for the Study of Lung Cancer (IASLC) TNM
(tumor-node-metastasis) classification, 7th edition [38].
Statistical methods
There were no missing data in our study. Survival was
estimated using the Kaplan-Meier method. Overallsurvival was measured from the date of the first course
of the initial therapy to the date of death or that of the
last follow-up examination. A log-rank test was performed
to evaluate the significance of differences in the overall
survival among the groups. P values < 0.05 were consid-
ered to be indicative of statistical significance. A multivari-
ate analysis using the Cox proportional hazards model
was used to establish the association between the clinical
variables and survival. All statistical analyses were carried
out using SPSS, version 11.0 for Windows (SPSS Inc.,
Chicago, IL, USA). To reduce the potential bias arising
from some patients dying too early to receive initial ther-
apy, the two patients who died within a month (30 days)
of the start of initial therapy were excluded from the
analysis.
Results
The cohort consisted of 284 patients who were diag-
nosed as having stage IIIB or IV lung adenocarcinoma
and had received initial therapy.
The clinical characteristics of the patients are summa-
rized in Table 1. The median patient age prior to the
start of initial therapy was 65 years (range, 23 to 87
years). The patients were predominantly younger than
70 years of age (81%), the ECOG PS was 0–2 in 93% of pa-
tients, and 91% of the patients had stage IV disease. While
the lung adenocarcinoma patients with EGFR mutations
were predominantly female (64%) and non-smokers
Table 1 Patient characteristics
Characteristic Mt + (n= 121) Mt – (n= 163) All (n= 284)
No. % No. % No. %
Age, years
Median (range) 66 (32–87) 65 (23–83) 65 (23–87)
< 70 97 80 134 82 231 81
≥ 70
24 20 29 18 53 19
Gender
Male 43 36 125 77 168 59
Female 78 64 38 23 116 41
ECOG PS
0-1 103 85 135 83 238 84
> 2 18 15 28 17 46 16
Smoking status
Yes 50 41 124 76 174 61
No 71 59 39 24 110 39
Stage
IIIB 6 5 19 12 25 9
IV 115 95 144 88 259 91
EGFR mutation
Exon 19 deletion 59 49 59 21
Exon 21 L858R 57 47 57 20
Exon 18 G719X 5 4 5 2
Wild type 163 100 163 57
PCV
Median (range) 1.6 (0.1-110.0) 2.3 (0.1-80.0) 2.0 (0.1-110.0)
< 2.2 ng/ml 72 60 78 48 150 53
≥ 2.2 ng/ml 49 40 85 52 134 47
CEA
Median (range) 8 (0.7-11942) 7 (0.5-14985) 7.4 (0.5-14985)
< 5.0 ng/ml 45 37 63 39 108 38
≥ 5.0 ng/ml 76 63 100 61 176 62
EGFR: epidermal growth factor receptor, Mt+: mutant EGFR, Mt-: wild-type EGFR, PCV: pretreatment CYFRA 21–1 value.
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male (77%) and smokers (76%).
Details about the first-line chemotherapy were available
for 284 patients including both patient groups with wild-
type (Mt-) and mutant EGFR (Mt+) groups (Table 2).
About 40% of the EGFR mutation-positive patients re-
ceived EGFR-TKIs as the initial treatment.
Carboplatin-paclitaxel, the treatment of choice across
both groups, was administered to half of the platinum
doublet cohort in the Mt- patient group. Meanwhile,
docetaxel was administered to half of the monotherapy
cohort in the same patient group. However, cisplatin-
pemetrexed was the most common regimen of second
choice across both the Mt+ and Mt- groups.The EGFR-TKI used for each treatment line in the Mt+
group is shown in Table 3. Forty-one (58%) patients re-
ceived gefitinib, while 16 (22%) received erlotinib as first-
or second-line treatment in the Mt+ group with PCV
(<2.2 ng/ml). Thirty-seven (73%) patients received
gefitinib, and 10 (20%) patients received erlotinib as first-
or second-line treatment in the Mt+ group with PCV
(≥2.2 ng/ml). Of the 121 patients in the Mt+ group, 27 did
not receive gefitinib at any treatment-line stage of treat-
ment; among these 27 patients, 19 received erlotinib (6 as
first-line, 10 as second-line, 1 as third-line and 2 as
further-line treatment). In the Mt+ group, a total of 113
patients (93%) received EGFR-TKIs, while 8 patients did
not receive EGFR-TKIs at any stage of treatment.
Table 2 Summary of initial treatment delivered among
284 patients
EGFR mutation Mt – (n= 163) Mt + (n= 121)
IIIB IV IIIB IV
(n= 19) (n= 144) (n= 6) (n= 115)
No. % No. % No. % No. %
Treatment
Platinum doublet 4 3 114 70 2 2 54 45
Monotherapy 0 30 18 0 11 9
EGFR-TKI 0 0 0 50 41
Chemoradiotherapy 15 9 0 4 3 0
Specific regimens
Cisplatin-pemetrexed 1 24 15 1 9 7
Carboplatin-paclitaxel 3 52 32 0 27 22
Carboplatin-paclitaxel+ bev 0 2 0 2
Other platinum doublets 0 36 22 1 12 10
Gefitinib 0 0 0 41 34
Erlotinib 0 0 0 7 6
Docetaxel 0 16 10 0 3
Vinorelbine 0 5 0 2
Others 0 24 15 0 6
Mt+: mutant EGFR, Mt-: wild-type EGFR, bev: bevacizumab.
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tients received EGFR-TKIs (11 as second-line, 7 as third-
line, 6 as fourth-line, 3 as fifth-line, 1 as sixth-line, 1 as
seventh-line, and 1 as eighth-line treatment). Fifty-three
patients (18%) were still alive at the time of the analysis.
The median follow-up period for determining the survival
was 39.3 (range; 11.8-84.9) months after the start of initial
therapy. The clinical variables identified by univariate ana-
lysis to be associated with significantly better survival
(Table 4) included female gender (MST 32.4 months ver-
sus 20.1 months in males: p = .0086), no smoking his-
tory (33.4 months versus 20.1 months in smokers, p =
.0012), ECOG PS (0–1) (29.5 months versus 7.9 monthsTable 3 Summary of EGFR-TKI delivered among EGFR
mutation positive patients
EGFR mutation positive
Low PCV High PCV
(< 2.2 ng/ml) (n= 72) (≥ 2.2 ng/ml) (n= 49)
Gefitinib Erlotinib Gefitinib Erlotinib
No. % No. % No. % No. %
First-line 20 28 5 7 23 47 2 4
Second-line 21 29 11 15 14 29 8 16
Third-line 9 12 6 8 3 6 4 8
Further-line 2 3 14 20 2 4 4 8
Unadministered 20 28 36 50 7 14 31 63
PCV: pretreatment CYFRA 21–1 value.in those with a PS of 2–3, p < .0001), presence of EGFR
mutation (39.2 months versus 17.8 months in patients
without EGFR mutations, p < .0001), PCV < 2.2 ng/ml
(38.6 months versus 15.0 months in those with PCV ≥ 2.2
ng/ml, p < .0001), serum CEA < 5.0 ng/ml (32.6 months
versus 21.0 months in those with serum CEA ≥ 5.0 ng/ml,
p = .036), start date of initial therapy before April 1, 2008
(34.1 months versus 19.3 months in the group that re-
ceived the initial therapy after April 1, 2008, p = .003) and
EGFR-TKI treatment (33.7 months versus 15.3 months in
the group not treated with EGFR-TKIs, p < .0001). Multi-
variate analysis identified EGFR mutation positivity (HR
0.53; 95% CI: 0.34-0.84, p = .0069) and PCV < 2.2 ng/ml
(HR 0.43; 95% CI: 0.31-0.59, p < .0001) as independent fa-
vorable prognostic factors. Another factor that was found
to be an independent prognostic indicator of overall sur-
vival was the PS (Table 4). The overall survival rates of pa-
tients with advanced lung adenocarcinoma with/ without
EGFR mutation are shown in Figure 2. Among the Mt+
patients, the prognosis was more favorable in the group
with PCV < 2.2 ng/ml (n = 70) than in the group with
PCV > 2.2 ng/ml (n = 48) (median survival time
[MST]: 67.0 vs. 21.0 months, p < 0.0001). Among the
patients with Mt- also, the prognosis was more favor-
able in the group with PCV < 2.2 ng/ml (n = 78) than
in the group with PCV ≥ 2.2 ng/ml (n = 86) (MST:
24.1 vs. 10.2 months, p < 0.0001).
Discussion
In the present study, we demonstrated PCV and EGFR
mutation status as independent prognostic factors in un-
treated advanced lung adenocarcinoma patients. We also
showed that PCV < 2.2 ng/ml was a predictor of a favor-
able outcome in both advanced lung adenocarcinoma
patients with wild-type and mutant EGFR.
Serum CYFRA 21–1 has been reported as a prognostic
factor in patients with a variety of cancer types, includ-
ing resectable NSCLC [39,40], biliary tract cancer [41],
urothelial cancer [42], head and neck cancer [43],
esophageal cancer [44], and cervical cancer [45].
A meta-analysis of CYFRA 21–1 as a prognostic indi-
cator in advanced NSCLC patients showed that the PCV
may be a reliable prognostic factor [29], however, since
non-adenocarcinoma accounted for 65% of the cases
and squamous cell carcinoma for 50%, the role of serum
CYFRA 21–1 as a prognostic indicator in the lung
adenocarcinoma population remained unclear. More-
over, in a study of PCV as a prognostic indicator in ad-
vanced NSCLC patients in whom gefitinib was used as
3rd-line or later therapy, adenocarcinoma accounted for
fewer than a half of the cases (47%) [30]. The EGFR mu-
tation status was not included as a variable in the ana-
lysis, and the test population was small, consisting of
only 50 patients.
Table 4 Variables associated with overall survival among 284 patients
Co-variable No. Univariate analysis Multivariate analysis
MST (months) P Variate OR 95% CI P
Age
< 70 231 22.8
> 70 53 24.3 0.625
Gender
Male 168 20.1
Female 116 32.4 0.0086 Female 1.06 0.75-1.58 0.75
Smoking status
Yes 174 20.1
No 110 33.4 0.0012 No smoking status 0.84 0.52-1.24 0.39
ECOG PS
0-1 238 29.5
>2 46 7.9 <.0001 PS 0-1 0.34 0.24-0.50 <.0001
Stage
IIIB 25 30.2
IV 259 22.5 0.269
EGFR mutation
Mt (+) 121 39.2
Mt (−) 163 17.8 <.0001 Mutant EGFR 0.53 0.34-0.84 0.0069
PCV
< 2.2 ng/ml 150 38.6
≥ 2.2 ng/ml 134 15.0 <.0001 < 2.2 ng/ml 0.43 0.31-0.59 <.0001
CEA
< 5.0 ng/ml 108 32.6
≥ 5.0 ng/ml 176 21.0 0.036 < 5.0 ng/ml 0.93 0.67-1.26 0.63
Start dates of IT
Before 1/ 4/ 2008 79 34.1 After 1/ 4/ 2008
After 1/ 4/ 2008 205 19.3 0.0030 0.73 0.50-1.15 0.07
EGFR-TKI treatment
Yes 143 33.7
No 141 15.3 <.0001 Yes 0.76 0.50-1.15 0.20
IT: initial therapy, PCV: pretreatment CYFRA 21–1 value, Mt(+): mutant EGFR, M(−): wild-type EGFR.
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of serum CYFRA 21–1 as a prognostic indicator in the
advanced lung adenocarcinoma population in the
present study. First, there could be a relationship be-
tween the serum levels of CYFRA 21–1 and the micro-
filament formation trend in the tumor cells [22]. CKs
are the principal structural elements of intracellular mi-
crofilaments. Microfilaments have been shown to be
heteropolymers formed from type I and type II keratins
which form the cytoskeleton. Moreover, while the CKs
(CKs 1, 2, 10/11), on which the degree of keratinization
within tumors depends, are strongly expressed in well-
differentiated squamous cell carcinomas, they are not
detected in the serum. The possibility that they arepreferentially removed by macrophages because of their
poor solubility has been suggested as the reason for the
failure to detect them in the serum [46]. By contrast, sol-
uble CK19 is degraded by tumor lysis and tumor necro-
sis and released into the blood. Therefore, serum levels
of CK19 may indicate the degree of cytoskeleton forma-
tion by microfilaments within the tumor cells. Second,
there may also be a relationship between serum CYFRA
21–1 levels and the degree of tumor differentiation to-
wards squamous epithelium. CKs with a relatively high
molecular mass tend to be associated with differentiation
into squamous cell carcinoma, while CKs with a rela-
tively low molecular mass tend to be associated with dif-
ferentiation into adenocarcinoma [47]. In a study in
Figure 2 Kaplan-Meier curves for overall survival in four groups, EGFR mutation status- stratified by PCV. M+: mutant EGFR, M-: wild-
type EGFR, PCV: pretreatment CYFRA 21–1 value.
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cells containing CK19 increased with decreasing degree
of differentiation into squamous cell carcinoma, and the
presence of intracellular CK19 was consistently demon-
strated in pure lung adenocarcinomas [25]. On the other
hand, a negative correlation between intracellular CK19
expression and serum CYFRA 21–1 levels has also been
shown [24]. Increase in the serum level of CYFRA 21–1
may also be the result of a greater degree of degradation
and release of intracellular CK19 into the serum with an
increasing tendency towards differentiation into squa-
mous cell carcinoma.
Because identical EGFR mutations have been seen in
both the adenocarcinoma component and squamous cell
carcinoma component in resected cases of adenosquamous
carcinoma [48], it has been suggested that the two compo-
nents may arise from a single clone [48,49]. Resected cases
of adenosquamous carcinoma have been reported to
account for 3% of all cases of NSCLC [50], and
adenosquamous carcinoma patients have also been
reported to have a poor prognosis [51]. The prognosis
of patients in whom the tumor tissue consists of a
mixture of mutant EGFR cells and wild-type EGFR
cells has been reported to be inferior to that of patients
with tumors consisting of only mutant EGFR cells, and
intratumor heterogeneity has also been investigated
[52]. On the other hand, there is a report suggesting
that no intratumor heterogeneity of EGFR expression
is found in mutant EGFR lung adenocarcinomas, and
also that no disparity is found between the EGFR mu-
tation status of the primary tumor and lymph node
metastasis [53].
There are several limitations of the present study. The
first is that it was a retrospective study conducted at a
single institution, and the possibility of a selection bias isundeniable. The prognosis of patients who received initial
therapy before April 1, 2008 was significantly superior to
that of those who received their initial therapy after 2008.
Because we started to perform EGFR mutation analysis in
routine clinical practice from April 1, 2008, there is the
possibility of a selection bias towards patients who re-
ceived the initial therapy before April 1, 2008. This is one
of the major limitations of our retrospective study. Some
studies have reported that EGFR mutations may be a posi-
tive prognostic factor for survival in advanced NSCLC pa-
tients, regardless of EGFR-TKI therapy [54,55]. Also in the
BR.21 trial, the median survival time was reported to be
longer in patients with mutant EGFR as compared to that
in patients with wild-type EGFR [56]. Although mutant
EGFR patients not treated with EGFR-TKIs were found to
be a confounding factor, we performed adjustment for the
confounding factor using a Cox proportional hazards
model. According to the univariate analysis, the date of
start of the initial therapy (before April 1, 2008) was a fa-
vorable prognostic factor. However, PCV < 2.2 ng/ml,
EGFR mutation positivity and PS 0–1 were found to be in-
dependent favorable prognostic factors after adjustment
for the date of start of the initial therapy. In this study,
while the MST (39.2 months) in the mutant EGFR group
was not favorable as compared to previous reports [57],
the mutant EGFR group with PCV < 2.2 ng/ml had a
more favorable prognosis than that of the mutant EGFR
group with PCV ≥ 2.2 ng/ml. The proportion of patients
who received erlotinib was less in the group with PCV ≥
2.2 ng/ml than in the group with PCV < 2.2 ng/ml, which
could have influenced the more favorable prognosis in the
group with PCV < 2.2 ng/ml than in the group with
PCV ≥ 2.2 ng/ml. All of the patients with advanced
lung adenocarcinoma in whom the diagnosis was made
after April 1, 2008 were tested for EGFR mutations at
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other histological types of lung cancer, the testing was
performed at the discretion of the attending physician.
Second, the follow-up period was inadequate, especially in
the mutant EGFR group with PCV < 2.2 ng/ml, and the
censored cases were conspicuous. There was also a prob-
lem with the stage distribution (there were relatively few
stage IIIB cases). Distant metastasis occurred in all of the
stage IIIB cases in which local treatment had been
performed, and all of the patients with disease recurrence
were tested for EGFR mutations. Moreover, significant
survival differences in stage IIIB/ IV were not found in the
univariate analysis. Furthermore, the treatment regimens
used in the stage IV cases were not standardized, with
each of the attending physicians administering any of the
various standard treatments used in routine clinical prac-
tice recommended by the guidelines of the Japan Lung
Cancer Society.
In advanced lung adenocarcinoma, which may be con-
sidered as a generalized systemic disease, it may be par-
ticularly difficult to determine the characteristics of an
entire heterogeneous tumor by tissue diagnosis alone
based on examining just one part of the tumor. Based
on the results of the present study, we propose that mu-
tant EGFR patients with serum PCV < 2.2 ng/ml have a
better prognosis than the mutant EGFR patients with
higher PCV.
Conclusions
The potential applications of PCV measurements might in-
clude identification of candidates in whom it might have
some prognostic value. Furthermore, PCV might be
regarded as a routine demographic variable having prognos-
tic value in patients with advanced lung adenocarcinoma.
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